

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hillsberg Sanford</u>	2. Date of Event Requiring Statement (Month/Day/Year) 09/03/2013	3. Issuer Name and Ticker or Trading Symbol <u>Genesis Biopharma, Inc [ GNBP ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> Officer (give title below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
(Last) (First) (Middle) 21900 BURBANK BLVD., THIRD FLOOR		10% Owner	
(Street) WOODLAND HILLS CA 91367		Other (specify below)	
(City) (State) (Zip)			

## Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	13,400,000 <sup>(1)</sup>	I	The Hillsberg Trust

## Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
	Date Exercisable	Expiration Date					Title
Market Cap Earn-Out <sup>(2)</sup>	07/24/2013	01/24/2015	Common Stock	6,750,000 <sup>(2)</sup>	0.02	I	The Hillsberg Trust

## Explanation of Responses:

1. Mr. Hillsberg acquired these securities on July 24, 2013 as consideration for his shares of common stock of Lion Biotechnologies, Inc., which company Genesis Biopharma, Inc. acquired by merger on that date. The merger agreement also provides that during the 12-month period following the merger, for each \$1,000,000 of gross proceeds received by Genesis from any financings, licensing or similar transaction (except from certain listed investors), Mr. Hillsberg will receive 450,000 additional shares of Genesis common stock, up to a maximum of 6,750,000.

2. Under the merger agreement between Lion Biotechnologies, Inc. and Genesis Biopharma, Inc., Mr. Hillsberg is also entitled to 6,750,000 additional shares of common stock if, during the 18 months following the closing of the merger, the closing price per share of Genesis common stock equals or exceeds \$0.04, as adjusted for any stock split reverse stock split, recapitalization or the like, and \$100,000 of Genesis common stock is traded for any 10 out of 30 consecutive trading days.

/s/ Sanford J. Hillsberg

09/11/2013

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.